As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal
Two Assets Outlicensed
The deal will help MorphoSys focus on lifting lackluster Monjuvi sales, and on bringing its promising myelofibrosis candidate pelabresib to market.
